<DOC>
	<DOCNO>NCT02014376</DOCNO>
	<brief_summary>The purpose study ass whether SD-101 cream ( 3 % 6 % ) effective treat lesion subject Simplex , Recessive Dystrophic , Junctional Epidermolysis Bullosa .</brief_summary>
	<brief_title>Study Effectiveness Safety SD-101 Subjects With Epidermolysis Bullosa</brief_title>
	<detailed_description>Epidermolysis Bullosa ( EB ) rare group inherit disorder manifest blister erosion skin case , epithelial liming organ , response little apparent trauma . There lack effective agent skin disorder involve blister lesion formation . Current approve therapy minimally effective safety issue . Scioderm develop SD-101 Dermal Cream [ 0 % ( vehicle ) , 3 % 6 % ] treatment lesion associate EB . The purpose study assess safety efficacy SD-101 cream ( 3 % 6 % ) vs. vehicle treatment lesion 48 subject Simplex , Recessive Dystrophic , Junctional Epidermolysis Bullosa . SD-101 cream [ contain 3 % 6 % vehicle ( 0 % ) ] apply topically , day entire body period 90 day . Subjects come study site target wound assess baseline . Selected target wound must least certain age within prespecified size range study entry . Photographic confirmation target wound location collect baseline , picture save first visit use confirm location target wound subsequent visit . The subject return study site visit 2,3,4 5 ( 14 , 30 , 60 90 day respectively ) target wind previously identify baseline , re-assessed level healing . In addition , change itch , pain , Body Surface Area ( BSA ) coverage blister lesion , scar heal target wound also assess visit .</detailed_description>
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<criteria>Informed Consent form sign subject subject 's legal representative ; subject age 18 capable provide assent , sign assent subject . Subject ( caretaker ) must willing comply protocol requirement . Diagnosis Simplex , Recessive Dystrophic , Junctional nonHerlitz EB . Subjects must 6 month age old . Subjects must 1 target wound within prespecified size range study entry Target wound must least certain age Subjects meet entry criterion outline inclusion criterion . Selected target wound clinical evidence local infection . Use investigational drug within 30 day enrollment . Use immunotherapy cytotoxic chemotherapy within 60 day enrollment . Use systemic topical steroidal therapy within 30 day enrollment . ( Inhaled steroid ophthalmic drop contain steroid allow ) . Use systemic antibiotic within 7 day enrollment . Current former malignancy . Arterial venous disorder result ulcerated lesion . Diabetes mellitus . Pregnancy breastfeed study . ( A urine pregnancy test perform ar screen female subject childbearing potential ) Females childbearing potential abstinent practice medically acceptable method contraception . Known history cardiac , hepatic , renal disease .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Epidermolysis Bullosa</keyword>
	<keyword>Simplex</keyword>
	<keyword>Recessive Dystrophic</keyword>
	<keyword>Junctional non-Herlitz</keyword>
</DOC>